Downloads
Abstract
Background: Mutated ALK has been identified as a major oncogene associated with familial and sporadic neuroblastomas. ALK expression in neuroblastoma and its correlations with clinical features remains controversial. This study investigates the correlations between ALK expression and some clinical features of neuroblastoma.
Methods: 90 cases of neuroblastoma at the Department of Histoembryology - Pathology, University of Medicine and Pharmacy, Ho Chi Minh City from 01/01/ 2018 to 12/31/2021, were stained with ALK (D5F3) antibody. The ALK expression and its correlation with some clinical features were investigated.
Results: ALK expression was 91.1% (82/90 cases), more than 50% positive for 4 + (> 75% of tumor cells). ALK protein expression did not correlate with age, sex, tumor location, stage, risk group, and MYCN genestatus. Most all cases with MYCN amplification were strongly positive for ALK.
Conclusion: Specific ALK positivity in neuroblastoma cells and negativity in normal tissues provides an opportunity for the development of ALK - targeting antibodies.
References
Maris JM, Hogarty MD, Bagatell R et al. Neuroblastoma. Lancet.2007;369(9579):2106-20.
George RE., Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. 2008;455(7215), 975-978.
Pugh TJ, Morozova O, Attiyeh EF et al. The genetic landscape of high-risk neuroblastoma. 2013;45(3), 279-284.
Carén H, Abel F, Kogner P et al. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. 2008; 416(2), 153-159.
Passoni L, Longo L, Collini P et al. Mutation - independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. 2009;69(18), 7338-7346.
Lamant L, Pulford K, Bischof D et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. 2000;156(5), 1711-1721.
Carpenter EL., Haglund EA., Mace EM et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. 2012; 31(46), 4859- 4867.
Yan B, Kuick CH, Lim MS et al. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. 2014;9(9), e106575.
Lee JW, Park SH, Kang HJ et al. ALK protein expression is related to neuroblastoma aggressiveness but is not independent prognostic factor. 2018;50(2), 495.
Osajima - Hakomori Y, Miyake I, Ohira M et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. 2005;167(1), 213-222.
Wang M, Zhou C, Sun Q et al. ALK amplification and protein expression predict inferior prognosis in neuroblastomas. 2013; 95(2), 124-130.
Sternberg SS., Mills, SE., CarterD. Sternberg’s diagnostic surgical pathology. Lippincott Williams & Wilkins; 2004,1725-1726.
Monclair T, Brodeur GM., Ambros PF et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol, 2009; 27(2), 298-303.
Bệnh viện Nhi Đồng 2. Hướng dẫn điều trị nhi khoa 2019. Nhà xuất bản Y học; 2019,735-736.
Duijkers FAM., Gaal J, Meijerink JPP et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. 2012;180(3), 1223-1231.
Kim EK., Kim S. ALK gene copy number gain and immunohistochemical expression status using three antibodies in neuroblastoma. Pediatric and Developmental Pathology, 2017;20(2), 133-141.
Sano R, Krytska K, Larmour CE et al. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Science translational medicine, 2019; 11(483), eaau9732.
Aygün Z, Batur Ş, Emre Ş et al. Frequency of ALK and GD2 expression in neuroblastoma. Fetal and Pediatric Pathology, 2019;38(4), 326-334.
Tô Thùy Nhi, Nguyễn Thụy Minh Nhi, Nguyễn Hoàn Châu và cộng sự. Kết quả điều trị u nguyên bào thần kinh tại Bệnh viện Nhi Đồng 2. Tạp chí Ung thư học Việt Nam; 2018;2:146-151.
IARC. WHO Classification of Tumours of Endocrine Organs. International Agency for Research on Cancer Lyon, France; 2017,296-203.
Zhu S, Lee JS., Guo F et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. 2012;21(3), 362-373.
Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma.2008;455(7215), 971-974.
Reiff T, Huber L, Kramer M., et al. Midkine and Alk signaling in sympathetic neuron proliferation andneuroblastoma predisposition. Development, 2011;138:4699-4708.
| Published | 04-08-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.15 | |
| Keywords | U nguyên bào thần kinh, ALK, MYCN Neuroblastoma, ALK, MYCN |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital